Bolt Biotherapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 30, 2022. This is an annual report, and the provided filing text does not give standalone fourth-quarter results.
Business context
Bolt is a clinical-stage biotechnology company developing cancer immunotherapies based on its Boltbody immune-stimulating antibody conjugate (ISAC) platform and myeloid-cell biology. It has no approved products and has not generated product-sales revenue. Its lead candidate, BDC-1001, is in a Phase 1/2 trial for HER2-expressing solid tumors. BDC-2034 and BDC-3042 remain in preclinical development; a PD-L1 ISAC program is also preclinical. Bolt completed its IPO in February 2021.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Collaboration revenue | $1.3 million | $0.2 million |
| Research and development expense | $75.7 million | $40.4 million |
| General and administrative expense | $18.4 million | $9.1 million |
| Operating loss | $92.8 million | $49.2 million |
| Net loss | $98.6 million | $60.7 million |
| Operating cash used | $57.1 million | $47.3 million |
Revenue came from collaboration arrangements, not product sales. Net loss per share was $2.97 in 2021 versus $28.89 in 2020; the share-count comparison is affected by the 2021 IPO and conversion of preferred stock to common stock. Comprehensive loss was $98.9 million in 2021, including a $0.3 million unrealized investment loss. No operating margin is presented as a meaningful product-business measure at this pre-commercial stage.
At December 31, 2021, cash and cash equivalents were $27.4 million and marketable securities were $244.2 million, totaling approximately $271.6 million. Current assets were $189.2 million and current liabilities $21.3 million. Total liabilities were $57.6 million; the filing does not report borrowings or interest-bearing debt. Stockholders’ equity was $250.1 million. Management said available cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months after the report’s issuance, subject to assumptions and development spending.
Financing cash flow was $311.1 million, principally reflecting $244.3 million of net IPO proceeds and $51.9 million from the January 2021 preferred-stock financing. Investing cash flow was a $232.2 million use, largely due to purchases of marketable securities. The company reported an accumulated deficit of $207.0 million and expects ongoing losses and significant spending.
Changes versus prior year
- Net loss increased by $37.9 million, while operating expenses rose $44.6 million. R&D expense increased $35.3 million, mainly from manufacturing, personnel, facilities and clinical-trial activity; G&A increased $9.3 million, including higher personnel and professional-services costs.
- Collaboration revenue rose by $1.0 million, principally from Genmab services; 2020 revenue was from Toray.
- Operating cash use increased by $9.8 million. Cash and investments grew substantially following the IPO and other financings.
- The $6.1 million 2021 expense from remeasuring the preferred-stock purchase-right liability was non-recurring in nature; the liability was settled and reclassified to equity in January 2021. The comparable 2020 fair-value expense was $11.7 million.
Outlook, commentary and key risks
- BDC-1001: Interim data as of October 6, 2021 covered 57 heavily pretreated patients. The company reported no dose-limiting toxicities, two drug-related serious adverse events, and disease control (stable disease or partial response) in 13 of 40 evaluable patients. One partial response had persisted for more than 60 weeks at the update. These are early, non-pivotal results; dose escalation continued, and management expected to report updates and select recommended Phase 2 doses during 2022.
- Pipeline milestones: Management expected BDC-2034 to enter clinical testing in 2022 and anticipated an IND submission for BDC-3042 in 2023. These are forward-looking expectations, not assured outcomes.
- Collaborations: Genmab and Innovent fund specified research and development work through initial clinical proof of concept, with potential milestone and royalty economics. BMS supplies nivolumab at no cost for the combination trial, while Bolt funds and conducts the initial trial. Bolt noted that Toray and Bolt were reevaluating their research plan, which could affect collaboration scope and timing.
- Principal risks: Substantial continuing cash needs; clinical, regulatory and manufacturing uncertainty; reliance on third-party manufacturers and suppliers; competition; intellectual-property and licensing exposure; and possible COVID-19-related effects on trials and supply chains. Management reported no material COVID-19 impact on productivity or assets through year-end but said future effects remained uncertain.
- Controls and audit: Management identified a material weakness in internal control over financial reporting, tied to insufficient accounting personnel, formal processes and segregation of duties. Disclosure controls were judged ineffective. No misstatement was identified, and remediation was ongoing. The auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Other matters: No material pending legal proceedings were reported. The company had no cash-dividend policy in the foreseeable future. It reported federal and state NOL carryforwards of $178.1 million and $168.5 million, respectively, but had not completed a Section 382 ownership-change study; use of tax attributes may be limited.
Important facts for investors to verify
- Latest BDC-1001 safety, efficacy, evaluable-patient and dose-escalation results, including whether the early response and disease-control signals are confirmed in larger studies.
- Actual timing and cost of the planned BDC-1001, BDC-2034 and BDC-3042 clinical milestones, and whether the stated cash runway remains adequate as programs advance.
- Progress and terms of Bolt’s collaborations, including Toray’s research-plan reevaluation and the conditions for Genmab and Innovent options, milestones and royalties.
- Remediation and independent testing of the material weakness in financial reporting controls.
- Manufacturing capacity, supplier continuity, clinical-trial enrollment and any effects from competition, regulation or intellectual-property challenges.